Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib

PURPOSE: When during cancer treatment resistance to a tyrosine kinase inhibitor (TKI) occurs, switching to another TKI is often considered as a reasonable option. Previously, we reported that resistance to sunitinib may be caused by increased lysosomal sequestration, leading to increased intracellul...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cell Oncol (Dordr)
Главные авторы: Gotink, Kristy J., Rovithi, Maria, de Haas, Richard R., Honeywell, Richard J., Dekker, Henk, Poel, Dennis, Azijli, Kaamar, Peters, Godefridus J., Broxterman, Henk J., Verheul, Henk M. W.
Формат: Artigo
Язык:Inglês
Опубликовано: Springer Netherlands 2015
Предметы:
Original Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4555235/
https://ncbi.nlm.nih.gov/pubmed/25665527
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13402-015-0218-8
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы